Protalix Faces New Competition For Gaucher’s Disease Treatment

August 21, 2014 | Protalix Biotherapeutics is set to face a more competitive market for its treatment for Gaucher’s disease. The US Food & Drug Administration approved for marketing a new drug for the treatment of the genetic disease – Cerdelga made by Sanofi. Protalix’s flagship drug to treat Gaucher’s disease was also approved by the FDA for marketing and the company has a cooperation agreement with pharmaceutical giant Pfizer, which markets the drug everywhere except for Israel and Brazil. Gaucher’s disease is a genetic disease in which fatty substances accumulate in the cells and organs. Protalix was founded in 1993 by Yoseph Shaaltiel and is headquartered in Carmiel, Israel.